Multimodal treatment of resectable pancreatic ductal adenocarcinoma. 2017

Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
Medical Oncology Unit, Cancer Institute "Giovanni Paolo II", Bari, Italy. Electronic address: n.silvestris@oncologico.bari.it.

After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy
D059248 Chemoradiotherapy Treatment that combines chemotherapy with radiotherapy. Concurrent Chemoradiotherapy,Concomitant Chemoradiotherapy,Concomitant Radiochemotherapy,Concurrent Radiochemotherapy,Radiochemotherapy,Synchronous Chemoradiotherapy,Chemoradiotherapies,Chemoradiotherapies, Concomitant,Chemoradiotherapies, Concurrent,Chemoradiotherapies, Synchronous,Chemoradiotherapy, Concomitant,Chemoradiotherapy, Concurrent,Chemoradiotherapy, Synchronous,Concomitant Chemoradiotherapies,Concomitant Radiochemotherapies,Concurrent Chemoradiotherapies,Concurrent Radiochemotherapies,Radiochemotherapies,Radiochemotherapies, Concomitant,Radiochemotherapies, Concurrent,Radiochemotherapy, Concomitant,Radiochemotherapy, Concurrent,Synchronous Chemoradiotherapies
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic
D021441 Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS. Pancreatic Ductal Carcinoma,Carcinoma, Ductal, Pancreatic,Duct-Cell Carcinoma of the Pancreas,Duct-Cell Carcinoma, Pancreas,Ductal Carcinoma of the Pancreas,Pancreatic Duct Cell Carcinoma,Carcinoma, Pancreas Duct-Cell,Carcinomas, Pancreas Duct-Cell,Carcinomas, Pancreatic Ductal,Duct Cell Carcinoma of the Pancreas,Duct Cell Carcinoma, Pancreas,Duct-Cell Carcinomas, Pancreas,Ductal Carcinoma, Pancreatic,Ductal Carcinomas, Pancreatic,Pancreas Duct-Cell Carcinoma,Pancreas Duct-Cell Carcinomas,Pancreatic Ductal Carcinomas

Related Publications

Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
June 2022, Chirurgia (Bucharest, Romania : 1990),
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
January 2019, Clinical advances in hematology & oncology : H&O,
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
March 2015, Nihon rinsho. Japanese journal of clinical medicine,
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
January 2019, Digestive surgery,
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
October 2017, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
September 2023, Gut and liver,
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
May 2019, Annals of hepato-biliary-pancreatic surgery,
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
August 2019, Journal of clinical medicine,
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
January 2023, Cancer control : journal of the Moffitt Cancer Center,
Nicola Silvestris, and Oronzo Brunetti, and Enrico Vasile, and Francesco Cellini, and Ivana Cataldo, and Valeria Pusceddu, and Monica Cattaneo, and Stefano Partelli, and Mario Scartozzi, and Giuseppe Aprile, and Andrea Casadei Gardini, and Alessio Giuseppe Morganti, and Vincenzo Valentini, and Aldo Scarpa, and Massimo Falconi, and Angela Calabrese, and Vito Lorusso, and Michele Reni, and Stefano Cascinu
January 2023, Digital health,
Copied contents to your clipboard!